3,000 Daily Steps Slow Alzheimer's Decline, Study Finds — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Researchers followed almost 300 older adults with early Alzheimer's signs for 9 to 11 years using pedometers and found that more active participants experienced nearly half the cognitive and functional decline of sedentary peers.
- The study found exercise did not reduce toxic amyloid plaques — the target of most current Alzheimer's drugs — but instead reduced accumulation of misfolded tau proteins in specific brain regions tied to cognitive decline.
- Benefits appeared at just 3,000 daily steps, roughly half an hour of moderate walking, with optimal protection at 5,000 to 7,500 steps before the effect plateaued — undercutting the popular 10,000-step benchmark.
- Confounders complicate the picture: more active participants also had better cardiovascular health, lower cholesterol, improved sleep and lower blood pressure, making it difficult to isolate exercise's independent effect on the brain.
- Reverse causation is a possibility the authors flag — people with early Alzheimer's symptoms such as hearing loss often reduce activity before other signs appear, potentially creating a downward spiral rather than exercise driving protection.
- Supporting UK research includes a 78,430-person accelerometer study finding a 25% dementia risk reduction at 3,800 daily steps, rising to 50% at 9,800 steps, and a smaller Nordic-walking study of 15 people with mild-to-moderate Alzheimer's whose brain function was maintained over 24 weeks while 15 controls declined.
- Limitations include a small, mostly white, well-educated US cohort and the researchers' inability to fully account for clustered healthy habits — exercise, diet, non-smoking and heart health tend to travel together.
Why it matters: The study positions exercise as acting on tau pathology rather than amyloid plaques — the target of most current Alzheimer's drugs — pointing to a pathway existing pharmaceuticals don't address. The 3,000-step threshold gives sedentary older adults a realistic, evidence-grounded goal, though the small, homogeneous US sample and confounders like cardiovascular health limit causal conclusions.
Ask SkimNews
